Meet the Editorial Board Member

Christian C. Felder
Lilly Corporate Center
Indianapolis, IN
USA


Christian C. Felder

Dr. Christian Felder received a BS degree in Chemistry from the College of William and Mary, and his PhD in Biochemistry from the Georgetown University School of Medicine. He is currently a Research Fellow in the Neuroscience Division at Eli Lilly & Co. in Indianapolis where he leads a drug development research lab focused on neurological and neuropsychiatric diseases. He is also the program Director for the external Lilly Innovation Fellowship Awards program (LIFA) and internal Lilly Research Labs post doc program. Dr. Felder has published over 130 scientific articles, reviews and book chapters and has had numerous invitations to speak at universities and international scientific conferences.

SELECTED PUBLICATIONS

[1] Felder, C.C., Goldsmith, P.J., Jackson, K., Sanger, H.E., Evans, D.A., Mogg, A.J. Broad, L. M. Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. *Neuropharmacology*, **2018**, *136*(Pt C), 449-458.

[2] Felder, C.C. Strategic Research Institute G-Protein-Coupled Receptors Drug Discovery World Summit. *Expert Opin. Investig. Drugs*, **2004**, *13*(8), 1071-4.

[3] Howlett, A.C., Barth, F., Bonner, T.I., Cabral, G., Casellas, P., Devane, W.A. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. *Pharmacol. Rev.*, **2002**, *54*(2), 161-202.

[4] Felder, C.C., Joyce, K.E., Briley, E.M., Mansouri, J., Mackie, K., Blond, O., Lai, Y.Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol. Pharmacol.*, **1995**, *48*(3), 443-450.

[5] Porter, A.C., Sauer, J.M., Knierman M .D., Becker, G.W., Berna, M.J., Bao, J. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. *J. Pharmacol. Exper. Ther.*, **2002**, *301*(3), 1020-1024.

[6] Glass, M., Felder, C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. *J. Neurosci.*,**1997**, *17*(14), 5327-5333.

[7] Buckley, N.E., McCoy, K.L., Mezey, É., Bonner, T., Zimmer, A., Felder, C. C. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. *Eur. J. Pharmacol.*, **2000**, *396*(2-3), 141-149.

[8] Coussens, N.P.; Sittampalam, G.S.; Jonson, S.G.; Hall, M.D.; Gorby,H.E.; Tamiz, A.P.; McManus, O.B.; Felder, C.C.; Rasmussen, K. The opioid crisis and the future of addiction and pain therapeutics. *J. Pharmacol. Exp. Ther.*, **2019**, *371*(2), 396-408.

[9] Felder, C.C. GPCR drug discovery-moving beyond the orthosteric to the allosteric domain. *Adv. Pharmacol.*, **2019**, *86*, 1-20.

1570-159X/22